Economic Model Reveals Best Therapies

JUNE 01, 2005

A joint study from UCLA and the Veterans Affairs Greater Los Angeles Healthcare System found that the combination of a common nonsteroidal anti-inflammatory drug (NSAID) and an acid-lowering drug is both cost-effective and treatment-effective. The study team compared 3 therapies for treating arthritis: (1) an NSAID, such as ibuprofen or naproxen; (2) an NSAID with an acid-reducer (proton pump inhibitor; PPI), such as lansoprazole (Prevacid) or esomeprazole magnesium (Nexium); and (3) a cyclooxygenase-2 (COX-2) inhibitor, such as rofecoxib (Vioxx) or celecoxib (Celebrex).

The results showed that, for high-risk patients, an OTC NSAID used with a PPI was the safest and most cost-effective treatment. Study author Dr. Brennan Spiegel, codirector of the Center for the Study of Digestive Healthcare Quality and Outcomes, remarked, "COX-2 inhibitors were not a health economic bargain at all-especially given the added costs of more heart attacks."



SHARE THIS SHARE THIS
0

Conference Coverage

Check back here regularly for live conference coverage from the American Academy of Pain Medicine and the upcoming American Pharmacists Association Meeting and Expo. 


Pharmacy Times Strategic Alliance
 

Pharmacist Education
Clinical features with downloadable PDFs


Next-Generation Pharmacist® Awards


3rd Annual Convenient Healthcare and Pharmacy Collaborative Conference


SIGN UP FOR THE PHARMACY TIMES NEWSLETTER
Personalize the information you receive by selecting targeted content and special offers.